Natural autoreactive monoclonal IgM antibodies can promote central nervous system (CNS) protection and repair. These repair-promoting IgM antibodies have characteristics of classic natural autoreactive antibodies. For example, they are generally of the IgM isotype; encoded by germline genes with few somatic mutations; and polyreactive with low affinity with a range of structurally unrelated self and nonself antigens, specifically cytoskeleton, nuclear proteins, and DNA. 1 In addition, natural autoreactive monoclonal antibodies that promote CNS protection and repair bind specifically to surface plasma membrane antigens, which activate intracellular signals that promote neuron or glial cell survival 2, 3 and cross the blood-brain barrier to accumulate within injured regions of the CNS. 4 Other independent investigators have also demonstrated that human natural autoreactive monoclonal antibodies cross the blood-brain barrier and localize to normal and injured CNS tissues in vivo. 5 The therapeutic human IgM antibodies bind to membrane antigens, which are destroyed following treatments that disrupt cellular architecture, including chemical/ biochemical fixation, dehydration, solubilization, extraction or digestion, and physical/mechanical crush forces or extreme temperatures. 6, 7 The human IgM antibodies demonstrate specific affinity only when membranes are maintained under live physiological conditions. [6] [7] [8] Cell signals are activated through direct antibody-proteinglycolipid binding interactions. 2, 3, [9] [10] [11] 
IDENTIFICATION OF OLIGODENDROCYTE BINDING ANTIBODIES THAT PROMOTE CNS REPAIR
We used a novel strategy to identify human monoclonal antibodies that promote remyelination. 12 Monoclonal antibodies were isolated from the serum samples of patients with monoclonal gammopathy. Selection criteria included a serum monoclonal immunoglobulin concentration of greater than 3 g/dL and a lack of neurologic or antibody-associated pathologies. We screened antibodies for binding to myelin in live CNS tissue slices and to the surface of live oligodendrocytes in culture. 12 Six of 52 serum-derived human IgM antibodies (sHIgM) and zero of 50 serum-derived human IgG antibodies bound in these assays. Two IgM antibodies (sHIgM22 and sHIgM46) promoted significant remyelination in vivo. 12 A recombinant version of sHIgM22, rHIgM22, was engineered by cloning the antibody variable region DNA sequence into an expression vector. 9, 13 The antibody rHIgM22 promoted myelin repair in Theiler's virus infection-induced model of multiple sclerosis equal to the serum-derived form. 9 Gram quantities of GMP-grade rHIgM22 have been purified for formal toxicology studies prior to phase 1 clinical trials. Our development of rHIgM22 established an infrastructure for rapid translation of additional human antibodies from basic science to clinical therapies.
We successfully used the same strategy to identify additional human IgM antibodies for testing in other models of neurologic injury and disease. Two neuronbinding antibodies (sHIgM12 and sHIgM42) stimulated neurite extension. 10 A dendritic cell-binding antibody (B7DC XAb) mediated melanoma tumor clearance from lungs.
14 Several ␤-amyloid (A␤1-40 and A␤1-42)-binding human antibodies will be tested in animal models of Alzheimer disease. This strategy for identifying human antibodies that directly signal cells has the potential to generate therapeutic antibodies for a broad range of human diseases.
SPECIFIC ANTIBODY-GLYCOLIPID-PROTEIN INTERACTIONS MEDIATE rHIgM22 BINDING TO BOTH MYELIN AND OLIGODENDROCYTE MEMBRANE SURFACE
Several mouse IgM antibodies, including A2B5, O1, O4, HNK-1, SCH79.08, and SCH94.03, bind oligodendrocytes and promote remyelination in mouse models of multiple sclerosis (Table) . 7 A2B5, O1, and O4 bind to surface glycolipid antigens on less differentiated oligodendrocytes.
15-17 HNK-1, SCH79.08, SCH94.03, and rHIgM22 bind to antigens on the surface of relatively mature oligodendrocytes and myelin. We hypothesized that antibody-mediated remyelination required binding to oligodendrocyte membrane glycolipids.
Binding IgM antibodies to CNS tissue from glycolipid knockout mice demonstrates that the molecules bound by rHIgM22 in CNS myelin depend on components of the glycolipid synthesis pathway. Binding of rHIgM22 to the plasma membrane requires the presence of a substrate of cerebroside sulfotransferase (Cst). Normally, the cerebroside galactosyltransferase (Cgt) enzyme converts ceramide to galactosylcerebroside in oligodendrocytes. Then the enzyme Cst converts galactosylcerebroside to sulfatide. Immunofluorescence of live CNS tissue slices demonstrates the strong affinity of rHIgM22 for densely myelinated axons in wild-type mice (Figure 1 ). rHIgM22 and antibodies against myelin oligodendrocyte glycoprotein, expressed on mature myelin, bound to densely myelinated fiber tracts and to individual myelinated axons in the cerebellum. In contrast, rHIgM22 affinity for white matter tracts was abolished in CNS tissue from mice lacking sulfatide (Cst [−/−] ). 18 Similarly, O4 antibody, which labels sulfatide, was absent in Cst (−/−) mice. In addition, rHIgM22 binding was not detected in other sulfatide-expressing tissues, including peripheral nervous system myelin and Schwann cells. These data support the hypothesis that rHIgM22 binding depends on 1 or more Cst-sulfated antigens present exclusively on the surface myelin of oligodendrocytes. rHIgM22 may target sulfatide or a number of sulfated antigens within the CNS, including glucosylcerebroside sulfate, lactosylceramind-3-sulfate, seminolipid, bis-sulphoganglio tetraosylceramide, and bis-sulphoganglio triaosylceramide. The data support the hypothesis that rHIgM22 recognizes a complex on oligodendrocytes dependent on 1 or more sulfated antigens at the myelin plasma membrane.
Oligodendrocytes express a repertoire of integrins during specific stages of development. Oligodendrocyte myelination correlates with the expression of laminin receptor ␣6␤1 and vitronectin/fibronectin receptors ␣v␤1, ␣v␤3, ␣v␤5, and ␣v␤8. 19 Recent studies in collaboration with Jens Watzlawik, PhD, and Richard Pagano, PhD, at Mayo Clinic demonstrate a colocalization of rHIgM22 with ␤ integrins on the plasma membrane of mature oligodendrocytes.
We propose that sulfated molecules and ␤ integrin facilitate specific rHIgM22 binding to myelin and oligodendrocytes. In addition, the pentameric structure of the IgM molecule is necessary for remyelination and may be critical to cross-linking these antigens on the oligodendrocyte surface and inducing intracellular repair signals. 
IDENTIFICATION OF NEURON-BINDING ANTIBODIES FOR CNS PROTECTION AND REPAIR
Two neuron-binding human IgM antibodies, sHIgM12 and sHIgM42, were identified using the strategy described earlier. 10 These antibodies supported in vitro CNS neurite extension equal to the potent neurite stimulatory molecule laminin. Both IgM antibodies bound to the surface of many types of cultured neurons but not to the surface of mature oligodendrocytes. Both IgM antibodies stimulated neurite extension in the presence of CNS myelin, which normally inhibits outgrowth. These 2 IgM antibodies are novel agents to promote neurite extension and are being tested in models of CNS disease where destructive of axons and neurons.
ANTIBODY-MEDIATED MEMBRANE REARRANGEMENT INITIATES SIGNALING
We propose that natural autoreactive antibodies activate endogenous cellular mechanisms to protect CNS neurons and oligodendrocytes. Remyelination-promoting IgM antibodies bind to the surface of oligodendrocytes. However, not all IgM antibodies that bind to oligodendrocytes promote remyelination. Oligodendrocyte binding did not perfectly predict the remyelinating potential of an IgM antibody in vivo. Therefore, IgM-mediated repair requires other mechanisms besides strict binding. Specific signaling events are also required. Antibodymediated signaling in oligodendrocytes is mediated through membrane rearrangement and microdomain signaling. 2 Recent studies have demonstrated that mouse IgM antibody O4 and rHIgM22 bound to the surface of unfixed primary oligodendrocytes diffusely at 4°C. However, allowing membrane rearrangement at 15°C resulted in small punctate structures indicative of signaling microdomain clustering. sHIgM42 under the same conditions exhibited a similar punctate membrane pattern on neurons (Figure 2) . Coincident with IgM-mediated membrane clustering on oligodendrocytes was the rapid activation of intracellular mitogen-activated protein kinases. The phosphorylation of several signaling proteins increased within 1 minute and persisted for 15 minutes in primary oligodendrocytes treated with rHIgM22.
REPARATIVE IgM ANTIBODIES INDUCE RAPID CALCIUM INFLUX AND INHIBIT APOPTOSIS
The in vivo remyelination-promoting ability of an antibody correlated with its ability to induce transient calcium influx in oligodendrocytes in culture.
3,9 rHIgM22 binding to the oligodendrocyte plasma membrane induced signaling cascades that downregulated caspase-3 activation to prevent apoptosis. In addition, rHIgM22 altered gene expression on calcium influx through CNQXsensitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) channels in oligodendrocytes. The neuron-binding antibodies sHIgM12 and sHIgM42 demonstrated robust rescue of cultured neurons from hydrogen peroxide-induced apoptosis.
ANTIBODY-MEDIATED ACTIVATION OF CNS PROTECTION AND REPAIR
Strong parallels in character exist between remyelinationpromoting IgM antibodies rHIgM22 and O4 and the neurite outgrowth-promoting IgM antibodies sHIgM42 and sHIgM12. This suggests a common membranerearrangement mechanism that recruits signaling mol- ecules into clustered microdomains and ultimately leads to specific cell responses in vitro and in vivo (Figure 3) . We propose this class of autoreactive antibodies activates the cellular process of CNS protection and repair through direct signaling cascades. Although each antibody reacts to unique cell-specific antigens, binding to the appropriate cells activates the target cell in a conserved manner. Defining the common signaling components regulating changes in specific cells may lead to an understanding of the underlying mechanism of antibodyinduced repair and result in the design of better strategies to promote remyelination and protect axons. 
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